Core Viewpoint - The company has received approval from the National Medical Products Administration (NMPA) for clinical trials of its innovative drug BIOS-0623-Z4, which targets adult cancer pain relief and is the first of its kind in its mechanism and indication [1] Group 1: Drug Development - BIOS-0623-Z4 is a non-opioid drug developed by the company, specifically designed for the treatment of adult cancer pain [1] - The drug is classified as a Class 1 medication and has no other drugs on the market with the same target mechanism and indication [1] - The clinical trial application for BIOS-0623-Z4 was accepted on July 10, 2025, and has been approved for clinical trials to relieve adult cancer pain [1] Group 2: Regulatory Approval - The approval was granted based on the review of the application in accordance with the Drug Administration Law of the People's Republic of China and relevant regulations [1] - The approval indicates that the clinical trial application meets the necessary requirements for drug registration [1]

Core Viewpoint - Changchun High-tech has submitted a listing application to the Hong Kong Stock Exchange, aiming to expand its market presence after being listed on the Shenzhen Stock Exchange. The company is recognized as a leading innovation-driven pharmaceutical group in China, with a comprehensive product portfolio across various drug categories [1]. Group 1: Company Overview - Changchun High-tech is a prominent pharmaceutical group in China, focusing on therapeutic biological agents, chemical drugs, vaccines, and traditional Chinese medicine, with capabilities in R&D, production, and commercialization across all major drug registration types [1]. - The company has established a competitive and diversified product matrix driven by a differentiated innovation strategy, leading to strong financial performance and sustainable growth [1]. Group 2: Product Development and Pipeline - As of September 23, 2025, Changchun High-tech has successfully launched 13 new drug products, including the first domestically developed shingles vaccine approved in January 2023 and the first innovative biological drug for acute gouty arthritis approved in June 2025 [2]. - The company is actively expanding the indications of its approved products to cover a broader patient population, such as the approval of Jin Sai Zeng for ISS and Turner syndrome in 2024, which addresses approximately 82.3% of the pediatric short stature population in China [2]. Group 3: Financial Performance - The company reported revenues of approximately RMB 126.27 billion, RMB 145.66 billion, RMB 134.66 billion, and RMB 66.03 billion for the fiscal years 2022, 2023, 2024, and the six months ending June 30, 2025, respectively. Corresponding profits for these periods were approximately RMB 42.15 billion, RMB 47.76 billion, RMB 27.08 billion, and RMB 9.32 billion [3].

Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Construction Investment International as the sole sponsor, indicating its intention to expand its market presence after being listed on the Shenzhen Stock Exchange [1][3]. Group 1: Company Overview - Changchun High-tech is a leading innovation-driven pharmaceutical group in China, covering therapeutic biological agents, chemical drugs, vaccines, and traditional Chinese medicine, with comprehensive capabilities in R&D, production, and commercialization across all major drug registration types [3][4]. - The company has established a strong and diversified product portfolio in various therapeutic areas, including endocrine and metabolic diseases, women's health, immune and respiratory diseases, tumors, vaccines, and traditional Chinese medicine [4]. Group 2: Financial Performance - The sales revenue of Changchun High-tech's pharmaceutical products reached RMB 12.7 billion in 2024, maintaining over RMB 10 billion for four consecutive years [3]. - The company has consistently ranked among the "Top 100 Pharmaceutical Enterprises in China" for eight consecutive years since 2017 [3]. - Revenue figures for the fiscal years 2022 to 2025 show a growth trajectory, with revenues of approximately RMB 126.27 billion, RMB 145.66 billion, RMB 134.66 billion, and RMB 66.03 billion for the first half of 2025 [5][7]. Group 3: Product Development and Pipeline - As of September 23, 2025, Changchun High-tech has over 40 candidate drugs in clinical stages or submitted for IND applications, including 14 in Phase III clinical trials or NDA stages and 15 first-class innovative drugs [5]. - The company has successfully launched 13 new drug products during the historical record period, including the first domestically developed shingles vaccine approved in January 2023 and the first innovative biological drug for acute gouty arthritis approved in June 2025 [4][5].

Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Construction Investment International as the sole sponsor, while already being listed on the Shenzhen Stock Exchange [1]. Group 1: Company Overview - Changchun High-tech is a leading innovation-driven pharmaceutical group in China, covering therapeutic biological agents, chemical drugs, vaccines, and traditional Chinese medicine, with capabilities across all major drug registration types in China [4]. - The company has established a competitive and diversified product matrix through a differentiated innovation strategy, leading to strong financial performance and a solid foundation for sustainable growth [4]. - In 2024, the sales revenue from pharmaceutical products is projected to reach RMB 12.7 billion, maintaining over RMB 10 billion for four consecutive years [4]. Group 2: Product Development and Pipeline - Changchun High-tech has developed a strong and diversified product portfolio in areas such as endocrine and metabolic diseases, women's health, immune and respiratory diseases, tumors, vaccines, and traditional Chinese medicine [5]. - The company has successfully launched 13 new drug products, including the first domestically developed shingles vaccine approved in January 2023 and the first innovative biological drug for acute gouty arthritis approved in June 2025 [5]. - As of September 23, 2025, the company has over 40 candidate drugs in clinical stages or submitted for IND applications, including 14 in Phase III clinical trials or NDA stages, showcasing potential for global first-in-class or best-in-class drugs [6]. Group 3: Financial Performance - For the fiscal years 2022 to 2025, the company reported revenues of approximately RMB 12.63 billion, RMB 14.57 billion, RMB 13.47 billion, and RMB 6.64 billion for the first half of 2025, respectively [6][8]. - The net profit for the same periods was approximately RMB 4.22 billion, RMB 4.78 billion, RMB 2.71 billion, and RMB 0.93 billion for the first half of 2025, indicating fluctuations in profitability [6][8].

Group 1 - The Hang Seng Healthcare Index rose by 1.22%, with notable increases in stocks such as InnoCare Pharma-B (up 7.03%) and Alibaba Health (up 4.51%) [2] - The Hang Seng Healthcare ETF (513060) saw a 4.55% increase over the past month, ranking in the top third among comparable funds [2] - The trading volume for the Hang Seng Healthcare ETF was active, with a turnover of 10.9% and a transaction value of 784 million yuan [2] Group 2 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index increased by 0.95%, with InnoCare Pharma-B leading the gains [3] - The Hong Kong Stock Innovative Drug Selection ETF (520690) experienced a slight decline of 0.20%, but had a 2.99% increase over the past month, ranking in the top half among comparable funds [3][5] - The trading volume for the Hong Kong Stock Innovative Drug Selection ETF was also active, with a turnover of 16.1% and a transaction value of 68.27 million yuan [5] Group 3 - The CSI Pharmaceutical 50 Index fell by 0.89%, with mixed performance among constituent stocks [6] - The Pharmaceutical 50 ETF (159838) decreased by 0.62%, but had a 2.37% increase over the past month [6] - The trading volume for the Pharmaceutical 50 ETF was lower, with a turnover of 1.45% and a transaction value of 2.39 million yuan [6] Group 4 - Rongchang Bio's "Taitasip" is set for priority review for treating IgA nephropathy, showing potential in reducing proteinuria [7] - CanSino announced an A-share restricted stock incentive plan and H-share stock option plan, aiming to motivate its core team with performance targets [7] - Borui Pharma plans to issue H-shares and list on the Hong Kong main board, reflecting an accelerated trend of A+H listings [7] Group 5 - The recent dynamics in the pharmaceutical sector highlight a focus on innovative drugs and capital operations, with Rongchang Bio's progress potentially boosting sector sentiment [8] - CanSino's incentive plan is expected to stabilize investor expectations by aligning core team interests with long-term performance [8] - Borui Pharma's cross-market strategy demonstrates the use of dual platforms to optimize capital structure, likely attracting investor attention [8] Group 6 - The Hang Seng Healthcare ETF has a latest scale of 7.148 billion yuan, ranking in the top third among comparable funds [12] - The Hong Kong Stock Innovative Drug Selection ETF reached a new high with a scale of 422 million yuan [13] - The Pharmaceutical 50 ETF tracks the top 50 pharmaceutical companies in A-shares, with the top ten stocks accounting for 58.68% of the index [14]

Core Viewpoint - Tianfeng Securities has revised down the revenue and net profit forecasts for Green Leaf Pharmaceutical for 2025 to 2026 due to intense market competition and centralized procurement impacts, while maintaining a "Buy" rating [1] Group 1: Financial Performance - The revenue forecast for Green Leaf Pharmaceutical has been adjusted from 85.29 billion and 102.79 billion to 66.38 billion and 74.47 billion for 2025 and 2026 respectively, with an expected revenue of 81.62 billion for 2027 [1] - The net profit forecast has been revised down from 13.73 billion and 16.78 billion to 6.72 billion and 8.31 billion for 2025 and 2026 respectively, with an expected net profit of 9.16 billion for 2027 [1] - In the first half of 2025, the company reported revenue of 31.81 billion, a year-on-year increase of 3.5%, while the net profit attributable to the parent company was 3.13 billion, a year-on-year decrease of 19.3% [1] Group 2: Business Focus and Product Development - The company is focusing on two major areas: CNS (Central Nervous System) and oncology, with multiple new products beginning commercialization and an increasing sales proportion of new products (up 32% year-on-year) [1] - In the oncology treatment sector, revenue reached 12.95 billion, a year-on-year increase of 13.5%, while CNS treatment revenue was 8.68 billion, up 5.4%. Cardiovascular treatment revenue was 6.93 billion, down 9.2%, and metabolic treatment revenue was 1.80 billion, down 7.9% [1] Group 3: New Product Commercialization - The company has successfully commercialized two major products in the CNS field, with Ruxinlin being the first domestically developed antidepressant included in the 2024 medical insurance directory, showing over 4 times year-on-year sales growth [2] - ERZOFRI, a product for treating schizophrenia, entered the U.S. market in April 2025, being the first of its kind developed by a Chinese company with independent intellectual property rights [2] - ERZOFRI has a long patent period until 2039 and is currently in a favorable competitive landscape with only two companies in the market [2] Group 4: Innovation Pipeline - The company has a rich pipeline of innovative drugs in development, actively seeking business development collaborations with multinational corporations [3] - LY03017, aimed at treating Parkinson's disease psychosis and Alzheimer's disease psychosis, is expected to complete Phase I clinical trials in China by the end of 2025, with IND approval anticipated in Q3 2025 [3] - Other innovative drugs, including LY03015 for tardive dyskinesia and Huntington's disease, are in Phase II clinical trials, with data expected in the first half of 2026 [3]

Core Viewpoint - Tianfeng Securities maintains a "Buy" rating for Shiyao Group, forecasting revenue and net profit growth from 2025 to 2027 despite a decline in 2025H1 performance due to comprehensive procurement execution and pressure on traditional medicine sales [1] Group 1: Financial Performance - In 2025H1, the company reported revenue of 13.273 billion yuan, a year-on-year decrease of 18.5%, and a net profit of 2.548 billion yuan, down 15.6% [1] - The traditional medicine business revenue was 10.248 billion yuan, including 1.075 billion yuan from licensing income, representing a year-on-year decline of 24.4% [2] - Excluding licensing income, product sales revenue fell by 32.3%, with significant declines in various therapeutic areas [1][2] Group 2: Licensing Income and Business Development - Licensing income has become a strong source of revenue and profit for the company, with a 120 million USD upfront payment for SYH2086 expected to contribute to future income [2] - The company has successfully executed six business development projects in 2024, highlighting the value of its eight R&D platforms [2] Group 3: Clinical Developments and Drug Approvals - SYS6010 has initiated overseas Phase III clinical trials, with positive early data recognized by regulatory authorities in both China and the U.S. [2] - The first domestic HER2 bispecific antibody, KN026, has had its new drug application accepted by the Chinese National Medical Products Administration, showing promising clinical trial results [3] - Multiple clinical data readouts are expected in 2025, with several ongoing trials across various cancer types [4]

Core Viewpoint - Tianfeng Securities maintains a "buy" rating for Shiyao Group (01093), forecasting revenue and net profit growth from 2025 to 2027 despite a decline in 2025H1 due to pressure from centralized procurement and a significant drop in traditional drug sales [1] Group 1: Financial Performance - In 2025H1, the company reported revenue of 13.273 billion yuan, a year-on-year decrease of 18.5%, and a net profit of 2.548 billion yuan, down 15.6% [1] - The traditional drug business saw a revenue drop of 24.4% to 10.248 billion yuan, with product sales declining by 32.3% when excluding authorized income [1] Group 2: Business Segments - Authorized income has become a significant source of revenue and profit for the company, with a 120 million USD upfront payment for SYH2086 expected to contribute to future earnings [2] - The company has established six business development (BD) projects in 2024, highlighting the value of its eight R&D platforms [2] Group 3: Clinical Developments - SYS6010 has initiated overseas Phase III clinical trials, with positive early data recognized by regulatory authorities in both China and the U.S. [3] - The HER2 bispecific antibody KN026 has had its new drug application accepted by the Chinese National Medical Products Administration, showing promising clinical trial results [4] - Multiple clinical data readouts are expected in 2025, including various ongoing trials for different cancer treatments [5]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Betta Pharmaceuticals Co., Ltd. 貝達藥業股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向貝達藥業股份有限公司（「本公司」）、其聯席保薦人、整體協調人、顧問或包銷團成員 表示同意： 本公司文件根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記前，本公司不 會向香港公眾人士提出要約或邀請。倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依 據呈交香港公司註冊處註冊的本公司文件作出投資決定；有關文本將於發售期內向公眾刊發。 (a) 本文件僅為向香港公眾人士提供有關本公 ...

Summary of Jin Xin Pharmaceutical Conference Call Company Overview - Jin Xin Pharmaceutical has completed centralized procurement and achieved stable revenue and profit growth by expanding its outpatient market [2][4]. Financial Performance - The projected non-deductible net profit for 2024 is approximately 630 million yuan, with expectations for double-digit growth in the coming years [2][4]. - For 2025, the estimated non-deductible net profit is expected to reach 700 million yuan, with total profit around 800 million yuan, supporting a market capitalization of 10-12 billion yuan [2][4]. Key Products and Innovations - The innovative insomnia drug, Tida Xini, is set to enter the medical insurance system in November 2024, priced higher than similar generic drugs [2][5]. - Tida Xini is expected to achieve sales of 180-200 million yuan in 2025, significantly exceeding market expectations of 500-800 million yuan, with potential to surpass 2 billion yuan in sales in the future, corresponding to a market cap of 6 billion yuan [2][5]. Research and Development - Jin Xin's oral LPA small molecule research is leading globally, currently in deep negotiations with overseas multinational corporations (MNCs) [2][6]. - Based on the valuation of similar transactions, the BD transaction valuation for Jin Xin's oral LPA is estimated to be at least 1.5-2 billion USD, corresponding to a market cap of approximately 10 billion yuan [2][6]. Strategic Direction - Jin Xin Pharmaceutical is committed to innovation and will continue to advance its research pipeline while actively expanding its projects in the psychiatric and neurological fields, enhancing the company's long-term investment value [3][7]. Market Position - The company has stabilized its core business after facing intense competition in centralized procurement during 2020 and 2021, successfully completing procurement for several products [4][5]. - The company’s strategic focus on innovative products and R&D positions it favorably in the pharmaceutical market, with a potential market cap of 30 billion yuan if key strategies are realized [4]. Additional Insights - Tida Xini's short half-life and lack of accumulation effects present significant innovation in the field of psychiatry, particularly for insomnia treatment [5]. - Jin Xin's progress in oral LPA small molecules is notable, being second only to Heng Rui and AstraZeneca in the small molecule sector [6]. This summary encapsulates the key points from the conference call, highlighting Jin Xin Pharmaceutical's financial outlook, product innovations, R&D advancements, and strategic direction.